Analysts Set Biogen Inc. (NASDAQ:BIIB) PT at $220.57

Shares of Biogen Inc. (NASDAQ:BIIB) have been given an average recommendation of “Moderate Buy” by the thirty-two brokerages that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $221.1071.

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Rothschild & Co Redburn raised their target price on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Finally, Canaccord Genuity Group upped their price target on shares of Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st.

Biogen Stock Up 1.9%

BIIB opened at $209.43 on Monday. The stock’s 50 day moving average price is $200.68 and its 200 day moving average price is $190.37. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. The stock has a market cap of $30.92 billion, a P/E ratio of 22.47 and a beta of 0.16. Biogen has a 12 month low of $124.56 and a 12 month high of $219.72.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same quarter in the previous year, the firm posted $5.47 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, research analysts predict that Biogen will post 11.28 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Biogen during the 4th quarter valued at $464,408,000. Boston Partners acquired a new stake in shares of Biogen in the fourth quarter valued at $302,815,000. Fred Alger Management LLC lifted its holdings in shares of Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after buying an additional 796,735 shares during the period. Employees Provident Fund Board bought a new position in Biogen during the fourth quarter valued at about $123,931,000. Finally, Orion Porfolio Solutions LLC boosted its stake in Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after buying an additional 509,809 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of approximately $2.74 billion, up 3.4% year over year and above the roughly $2.46 billion consensus estimate. Adjusted EPS of $3.60 also exceeded expectations, supporting the positive market reaction. Reuters article
• Positive Sentiment: The Growth Portfolio generated $1.06 billion in revenue, up 24% year over year and ahead of the legacy multiple sclerosis portfolio. SKYCLARYS, ZURZUVAE, and products acquired through the Apellis transaction—including SYFOVRE and EMPAVELI—provided important growth contributions. The Pharma Letter article
• Positive Sentiment: Biogen raised its full-year 2026 revenue outlook to mid-single-digit growth versus 2025, reflecting momentum in newer drugs and the Apellis acquisition. Analysts also highlighted pipeline progress, including encouraging early Alzheimer’s data for diranersen. Seeking Alpha article
• Neutral Sentiment: Leqembi sales continued to grow, reaching 29.3 billion yen globally in the quarter, but narrowly missed some expectations. The Alzheimer’s drug remains strategically important, although its near-term contribution is being weighed against commercialization costs and competition. Leqembi sales article
• Negative Sentiment: GAAP net income fell sharply to $97.5 million from $634.8 million a year earlier, while reported EPS declined to $0.66 from $5.47. Biogen’s updated 2026 non-GAAP EPS guidance of $12 to $13 is below the prior consensus estimate of $13.45, tempering the otherwise strong earnings reaction. The Wall Street Journal article
• Negative Sentiment: Legacy multiple sclerosis products remained under pressure, highlighting Biogen’s continuing dependence on successful execution of its newer rare-disease, Alzheimer’s, and acquired-product portfolio.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.